550 related articles for article (PubMed ID: 18306371)
21. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy.
Yee VS; Thompson JF; McKinnon JG; Scolyer RA; Li LX; McCarthy WH; O'Brien CJ; Quinn MJ; Saw RP; Shannon KF; Stretch JR; Uren RF
Ann Surg Oncol; 2005 Jun; 12(6):429-39. PubMed ID: 15886905
[TBL] [Abstract][Full Text] [Related]
22. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
23. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in patients with thick cutaneous melanoma (> 4 mm).
Zettersten E; Sagebiel RW; Miller JR; Tallapureddy S; Leong SP; Kashani-Sabet M
Cancer; 2002 Feb; 94(4):1049-56. PubMed ID: 11920475
[TBL] [Abstract][Full Text] [Related]
25. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
26. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
27. A long-term analysis of 620 patients with malignant melanoma at a major referral center.
Averbook BJ; Russo LJ; Mansour EG
Surgery; 1998 Oct; 124(4):746-55; discussion 755-6. PubMed ID: 9780997
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ
Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518
[TBL] [Abstract][Full Text] [Related]
29. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients.
Quinn MJ; Crotty KA; Thompson JF; Coates AS; O'Brien CJ; McCarthy WH
Cancer; 1998 Sep; 83(6):1128-35. PubMed ID: 9740077
[TBL] [Abstract][Full Text] [Related]
30. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in young women with cutaneous melanoma.
Burton AL; Egger ME; Quillo AR; Stromberg AJ; Hagendoorn L; Scoggins CR; Martin RC; McMasters KM; Callender GG
Am J Surg; 2014 Jan; 207(1):102-8. PubMed ID: 24330977
[TBL] [Abstract][Full Text] [Related]
32. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003.
Lasithiotakis KG; Leiter U; Gorkievicz R; Eigentler T; Breuninger H; Metzler G; Strobel W; Garbe C
Cancer; 2006 Sep; 107(6):1331-9. PubMed ID: 16909413
[TBL] [Abstract][Full Text] [Related]
33. Sarcopenia as a prognostic factor among patients with stage III melanoma.
Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
[TBL] [Abstract][Full Text] [Related]
34. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients.
Karakousis GC; Gimotty PA; Czerniecki BJ; Elder DE; Elenitsas R; Ming ME; Fraker DL; Guerry D; Spitz FR
Ann Surg Oncol; 2007 May; 14(5):1596-603. PubMed ID: 17285396
[TBL] [Abstract][Full Text] [Related]
35. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma.
Hoersch B; Leiter U; Garbe C
Br J Dermatol; 2006 Oct; 155(4):771-7. PubMed ID: 16965427
[TBL] [Abstract][Full Text] [Related]
36. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma.
de Vries M; Speijers MJ; Bastiaannet E; Plukker JT; Brouwers AH; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
Eur J Surg Oncol; 2011 Aug; 37(8):681-7. PubMed ID: 21636244
[TBL] [Abstract][Full Text] [Related]
38. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
[TBL] [Abstract][Full Text] [Related]
39. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
[TBL] [Abstract][Full Text] [Related]
40. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
